BR112015022849A2 - sais de adição de base de nitroxolina e usos dos mesmos - Google Patents

sais de adição de base de nitroxolina e usos dos mesmos

Info

Publication number
BR112015022849A2
BR112015022849A2 BR112015022849A BR112015022849A BR112015022849A2 BR 112015022849 A2 BR112015022849 A2 BR 112015022849A2 BR 112015022849 A BR112015022849 A BR 112015022849A BR 112015022849 A BR112015022849 A BR 112015022849A BR 112015022849 A2 BR112015022849 A2 BR 112015022849A2
Authority
BR
Brazil
Prior art keywords
nitroxoline
addition salts
base addition
pharmaceutical compositions
present
Prior art date
Application number
BR112015022849A
Other languages
English (en)
Other versions
BR112015022849B1 (pt
Inventor
Pan Ke
Original Assignee
Asieris Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asieris Pharmaceutical Tech Co Ltd filed Critical Asieris Pharmaceutical Tech Co Ltd
Publication of BR112015022849A2 publication Critical patent/BR112015022849A2/pt
Publication of BR112015022849B1 publication Critical patent/BR112015022849B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8

Abstract

resumo patente de invenção: "sais de adição de base de nitroxolina e usos dos mesmos". a presente invenção refere-se a novos sais de adição de base de nitroxolina com maior solubilidade e maior secreção na urina sob condições fisiológicas. as composições farmacêuticas e os processos de tratamento que utilizam as composições farmacêuticas também são descritos. a presente invenção refere-se a novos sais de adição de base de nitroxolina que possuem maior solubilidade e estabilidade em soluções aquosas quando comparados com a nitroxolina ou outros sais de nitroxolina. a presente invenção refere-se ainda a composições farmacêuticas que compreendem os sais de adição de base de nitroxolina e processos de tratamento ou de prevenção de doenças, distúrbios e estados de saúde que utilizam estas composições farmacêuticas. 1/1
BR112015022849-6A 2013-03-15 2014-03-17 Sais de adição de base de nitroxolina, usos e processo para preparação dos mesmos, bem como seu cristal, composição farmacêutica e processo para preparação da mesma BR112015022849B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790059P 2013-03-15 2013-03-15
US61/790,059 2013-03-15
PCT/US2014/030532 WO2014145723A1 (en) 2013-03-15 2014-03-17 Base addition salts of nitroxoline and uses thereof

Publications (2)

Publication Number Publication Date
BR112015022849A2 true BR112015022849A2 (pt) 2017-12-26
BR112015022849B1 BR112015022849B1 (pt) 2020-02-18

Family

ID=51538074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022849-6A BR112015022849B1 (pt) 2013-03-15 2014-03-17 Sais de adição de base de nitroxolina, usos e processo para preparação dos mesmos, bem como seu cristal, composição farmacêutica e processo para preparação da mesma

Country Status (12)

Country Link
US (1) US9758484B2 (pt)
EP (1) EP2970128B1 (pt)
JP (1) JP6273349B2 (pt)
KR (1) KR20160021077A (pt)
CN (1) CN105228984B (pt)
AU (2) AU2014232722B2 (pt)
BR (1) BR112015022849B1 (pt)
CA (1) CA2907338C (pt)
ES (1) ES2766758T3 (pt)
HK (1) HK1214589A1 (pt)
MX (1) MX357888B (pt)
WO (1) WO2014145723A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180129873A (ko) * 2016-03-31 2018-12-05 아시이리스 파머수티클 테크놀로지스 코퍼레이션 리미티드 암 치료에서 니트록솔린 및 그의 유사체의 화학요법 및 면역요법과의 조합적 사용
CN112402388A (zh) * 2019-08-05 2021-02-26 江苏亚虹医药科技股份有限公司 一种用于治疗膀胱癌的口服固体制剂及其制备方法
WO2021136381A1 (zh) 2019-12-31 2021-07-08 江苏亚虹医药科技股份有限公司 含硝羟喹啉的药物组合物、硝羟喹啉片剂及其制备方法和用途
CN111773193A (zh) * 2020-07-03 2020-10-16 江苏亚虹医药科技有限公司 含硝羟喹啉赖氨酸盐的药物组合物及其制备方法和用途
CN111960998A (zh) * 2020-08-03 2020-11-20 江苏亚虹医药科技有限公司 硝羟喹啉衍生物及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745834A (en) * 1953-02-09 1956-05-15 Phillips Petroleum Co Stabilization of certain vinyl-pyridines, vinyl quinolines and vinyl-isoquinolines
US2745832A (en) * 1954-03-08 1956-05-15 Nuodex Products Co Inc Metal quinolinolates and methods of making the same
US3872128A (en) 1972-03-08 1975-03-18 Union Carbide Corp Antimicrobial hydroxy quinoline, ethylene-acrylic polymer compositions
JPS5768831A (en) 1980-10-17 1982-04-27 Fuji Photo Film Co Ltd Heat developable photosensitive material
JPS57101835A (en) 1980-12-17 1982-06-24 Fuji Photo Film Co Ltd Thermodevelopable photosensitive material
US4329185A (en) 1981-01-21 1982-05-11 Dso "Pharmachim" Method for the preparation of a biologically active polyamide net
US5242892A (en) 1984-07-27 1993-09-07 The Board Of Trustees Of The University Of Illinois Chlorophyll biosynthesis modulators
JPH03284734A (ja) 1990-03-31 1991-12-16 Toshiba Corp 有機非線形光学材料
IT1317735B1 (it) 2000-01-26 2003-07-15 Nicox Sa Sali di agenti antimicrobici.
US7511137B2 (en) * 2003-12-19 2009-03-31 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
WO2006117660A2 (en) 2005-05-04 2006-11-09 Clio Pharmaceutical Corporation Method for treating cancer, coronary, inflammatory and macular disease, combining the modulation of zinc- and/or copper dependent proteins
EP2853600B1 (en) 2005-05-11 2018-09-19 ETH Zürich Recombinant N-glycosylated proteins from procaryotic cells
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US8729097B2 (en) * 2008-10-06 2014-05-20 The Johns Hopkins University Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders
EP2435036A2 (en) 2009-05-28 2012-04-04 Merck Patent GmbH Ammoniumcarboxylates
JP2010070557A (ja) 2009-12-17 2010-04-02 Anacor Pharmaceuticals Inc 加水分解抵抗性ホウ素含有治療薬および使用法
EP2353599A1 (en) 2010-01-28 2011-08-10 University of Ljubljana 8-hydroxyquinolines as inhibitors of cathepsin B
DK2730123T3 (da) * 2011-07-07 2020-03-02 Ericsson Telefon Ab L M Overleveringsbeslutning i betjenende basisstation baseret på en første og anden type mobilitetsmekanisme

Also Published As

Publication number Publication date
ES2766758T3 (es) 2020-06-15
CA2907338C (en) 2019-09-17
EP2970128B1 (en) 2019-12-04
JP6273349B2 (ja) 2018-01-31
KR20160021077A (ko) 2016-02-24
CN105228984B (zh) 2018-03-23
AU2014232722B2 (en) 2017-03-09
MX2015012720A (es) 2016-06-21
US20160031819A1 (en) 2016-02-04
CN105228984A (zh) 2016-01-06
AU2014232722A1 (en) 2015-09-24
WO2014145723A1 (en) 2014-09-18
AU2017200820A1 (en) 2017-03-02
MX357888B (es) 2018-07-27
EP2970128A4 (en) 2016-11-30
HK1214589A1 (zh) 2016-07-29
EP2970128A1 (en) 2016-01-20
CA2907338A1 (en) 2014-09-18
BR112015022849B1 (pt) 2020-02-18
JP2016514705A (ja) 2016-05-23
US9758484B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
BR112014026703A2 (pt) inibidores de dna-pk
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
BR112015017997A2 (pt) amidas de quinolina e quinazolina como moduladores de canais de sódio
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
BR112015025354A2 (pt) compostos di-hidropirido-pirimidínicos como inibidores de autotaxina
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112014023384A2 (pt) inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos
BR112017009583A2 (pt) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1
EA201391032A1 (ru) Новые гетероциклические производные и их применение в лечении неврологических расстройств
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014015845A8 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112015022849A2 (pt) sais de adição de base de nitroxolina e usos dos mesmos
BR112015019412A2 (pt) inibidores de bace1
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion)
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: ASIERIS PHARMACEUTICAL TECHNOLOGIES CO., LTD. (VG)

B25A Requested transfer of rights approved

Owner name: PAN-SCIENTIFIC HOLDINGS CO., LTD. (VG)

B25A Requested transfer of rights approved

Owner name: JIANGSU YAHONG MEDITECH CO., LTD. (CN)